Search

Your search keyword '"Erkan Dogan"' showing total 7 results
Start Over Author "Erkan Dogan" Publisher american society of clinical oncology (asco)
7 results on '"Erkan Dogan"'

1. Relation of tumor localization and metastasis sites in patients with breast cancer

Author

Sercan Aksoy, Cagatay Arslan, Didem Sener Dede, Yavuz Ozisik, Ibrahim Gullu, Özge Keskin, Omer Dizdar, Kadri Altundag, and Erkan Dogan

Subjects
Metastatic breast, Oncology, CA15-3, Cancer Research, medicine.medical_specialty, business.industry, Cancer, CA 15-3, medicine.disease, Primary tumor, Metastasis, Breast cancer, Internal medicine, medicine, In patient, skin and connective tissue diseases, business
Abstract

e21166 Background: We aimed to investigate whether a relation exists between primary tumor localization at breast and metastasis sites in breast cancer patients. Methods: Data of metastatic breast ...

Published
2011
Full Text
View/download PDF

2. Association between blood groups and breast cancer subtype

Author

Mustafa Solak, Erkan Dogan, Özge Keskin, Ibrahim Petekkaya, Cagatay Arslan, Fatma Paksoy Turkoz, M. K. Altundag, Neyran Kertmen, and Yavuz Ozisik

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Glycosylation, business.industry, Estrogen receptor, Breast cancer subtype, Favorable prognosis, chemistry.chemical_compound, chemistry, Internal medicine, medicine, Luminal type, business
Abstract

e11041 Background: The majority of breast carcinomas are the luminal type, which has the higher levels of estrogen receptor, tend to be low grade with a favorable prognosis. Altered glycosylation, ...

Published
2011
Full Text
View/download PDF

3. Body mass index in breast cancer subtypes

Author

Ibrahim Petekkaya, Cagatay Arslan, Özge Keskin, Yavuz Ozisik, Erkan Dogan, Kadri Altundag, Neyran Kertmen, and Mustafa Solak

Subjects
Oncology, Gynecology, Cancer Research, medicine.medical_specialty, business.industry, medicine.disease, Obesity, Breast cancer, Internal medicine, Medicine, Luminal type, skin and connective tissue diseases, business, Body mass index
Abstract

1117 Background: Obesity is related with luminal type breast cancer. The aim of this study is to evaluate the association between body mass index (BMI) and breast cancer subtypes. Methods: 1,255 br...

Published
2011
Full Text
View/download PDF

4. Evaluation of cardiac safety of lapatinib therapy for c-erbB2 amplified metastatic breast cancer

Author

Ibrahim Petekkaya, Yavuz Ozisik, Kadri Altundag, Hikmet Yorgun, N. Ozer, and Erkan Dogan

Subjects
Oncology, Cancer Research, medicine.medical_specialty, medicine.drug_class, business.industry, medicine.disease, Lapatinib, Metastatic breast cancer, Tyrosine-kinase inhibitor, respiratory tract diseases, Breast cancer, Internal medicine, medicine, skin and connective tissue diseases, business, medicine.drug
Abstract

e11001 Background: Lapatinib (L) is a tyrosine kinase inhibitor (TKI) that has efficacy in breast cancer. This study assessed the cardiac safety of lapatinib in women with cerbB-2 amplified metasta...

Published
2011
Full Text
View/download PDF

5. Addition of nine weeks of trastuzumab to adjuvant chemotherapy in operable HER2-positive breast cancer patients: Retrospective analysis

Author

Ibrahim Gullu, Cagatay Arslan, M. Ozen, D. Sener Dede, Erkan Dogan, Sercan Aksoy, Omer Dizdar, and M. K. Altundag

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Adjuvant chemotherapy, business.industry, Distant disease, Trastuzumab, HER2 Positive Breast Cancer, Internal medicine, medicine, Retrospective analysis, skin and connective tissue diseases, business, neoplasms, medicine.drug
Abstract

e13664 Background: Fin-HER study showed that addition of nine-weeks of trastuzumab to adjuvant chemotherapy improved disease-free survival and distant disease free survival in operable HER2-positiv...

Published
2010
Full Text
View/download PDF

6. Increased mean corpuscular volume of erythrocytes with capecitabine treatment in metastatic breast cancer patients: A marker of clinical benefit?

Author

Erkan Dogan, Omer Dizdar, Sercan Aksoy, Cagatay Arslan, Nilüfer Güler, Ibrahim Gullu, Yavuz Ozisik, D. Sener Dede, Mevlut Kurt, and M. K. Altundag

Subjects
Oncology, Cancer Research, medicine.medical_specialty, medicine.diagnostic_test, business.industry, medicine.drug_class, Complete blood count, Soft tissue, Mean age, medicine.disease, Gastroenterology, Metastatic breast cancer, Capecitabine, Estrogen, Internal medicine, medicine, business, Increased mean corpuscular volume, Mean corpuscular volume, medicine.drug
Abstract

1147 Background: We aimed to investigate the mean corpuscular volume (MCV) changes of red blood cells (RBC), and the possible association of clinical response in metastatic breast cancer patients (MBCP) under capecitabine treatment retrospectively. Methods: The data of 75 MBCP receiving capecitabine treatment between years of 2001 and 2005 were evaluated retrospectively. Capecitabine was used 2,500 mg2 daily for 14 days every 3 weeks. The complete blood count (CBC) including MCV (fl) was controlled at the beginning of capecitabine treatment, and periodically thereafter. ΔMCV was calculated by subtraction of MCV at the beginning from control date. Results: Forty-six of MBCP were premenopausal (61.3%). Mean age was 51.5 ± 10.8 years. Sixty-seven patients had invasive ductal carcinoma (89.4%). Estrogen and progesterone receptors were positive at 56% and 49% of the patients, respectively. Forty-eight patients (64%) had visceral, 11 had (14.7%) bone, 16 had soft tissue (21.3%) metastases. Capecitabine was admi...

Published
2010
Full Text
View/download PDF

7. Docetaxel/doxorubicin/cyclophosphamide (TAC) chemotherapy for operable HER2-negative, node-positive breast cancer patients: Results from a single institution

Author

Cagatay Arslan, D. Sener Dede, Omer Dizdar, Erkan Dogan, Kadri Altundag, Z. G. Surmeli, Sercan Aksoy, and Ibrahim Gullu

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, Cyclophosphamide, business.industry, medicine.medical_treatment, Node (networking), medicine.disease, Breast cancer, Docetaxel, Internal medicine, Docetaxel/doxorubicin, medicine, Doxorubicin, Single institution, skin and connective tissue diseases, business, neoplasms, medicine.drug
Abstract

e11106 Background: TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy is commonly used as adjuvant chemotherapy for node-positive breast cancer. However, data are lacking for HER2-negative s...

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results